Global Human Gene Sequencing Market Report 2021: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
Dublin, April 26, 2021 (GLOBE NEWSWIRE) -- The "Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to Consumer, by Country. With Executive and Consultant Guides. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.
Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
Will all newborns receive genetic testing at birth? Is COVID-19 holding the industry back? Where are the over 800 locations that have high throughput sequencing devices?
The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.
Key Topics Covered:
Human Gene Sequencing Markets - Strategic Situation Analysis & COVID Impact
Guide for Executives, Marketing, Sales and Business Development Staff
Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 Gene Sequencing Definition In This Report
1.1.1 Gene Sequencing
1.1.2 Hereditary
1.1.3 Newborn Screening
1.1.4 Non-invasive Prenatal Testing
1.1.5 Oncology
1.1.6 Pharmacogenomic
1.1.7 Direct to Consumer
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing
1.5 Genetic Testing vs. Gene Sequencing
1.5.1 Cost and Pricing Practice
1A Global Listing of Sequencer Installed Base - Location & Contacts
1A.1 Notes to Installed Base Listing
2. Market Overview
2.1 Market Participants Play Different Roles
2.1.1 Instrument Manufacturer
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Sequencing Labs
2.1.10 Audit body
2.2 Human Gene Sequencing -Markets, Examples and Discussion
2.2.1 Inherited Disease - Not what it used to be
2.2.1.1 Clinical and Research Lines Blur
2.2.1.2 Genetic Counselling - Not so simple anymore
2.2.1.3 The Genetic Blizzard - Issues of Access and Payment
2.2.2 Newborn Screening - The Standard of Care
2.2.2.1 Newborn Screening - Do Parents Want to Know?
2.2.3 NIPT - We've Only Just Begun
2.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
2.2.3.2 NIPT in the Future - Beyond Inherited Disease
2.2.4 Oncology - Understanding Two Worlds
2.2.4.1 The Tumor - A Sequence of Sequencing
2.2.4.2 The Tumor - Biopsy and Liquid Biopsy
2.2.4.3 The Human Genome - Predisposition and Prognosis
2.2.5 Pharmacogenomics
2.2.5.1 Sequencing Not the Only Player
2.2.5.2 New Roles for Old Drugs - A Research Bonanza?
2.2.6 Direct To Consumer - More Than Meets the Eye
2.2.6.1 DTC - How Many Segments?
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 The Rise of the Sequencing Lab
2.3.3 Sequencing as a Commodity
2.3.4 Informatics
2.3.5 Instrument Manufacturer Role
2.3.6 Healthcare Industry Impacts - Still Struggling
2.3.7 Can the Healthcare Industry Adapt?
2.3.8 Genetic Counselling as an Industry
2.3.9 Sequencing Adoption and Cannibalization
3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnoses
3.1.2 Wellness and Prevention
3.1.3 Fertility Technology
3.1.4 Cancer - Screening, Management and Monitoring
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs
3.2.3 Healthcare Cost Concerns Curtail Growth
3.2.4 Wellness has a downside
3.3 Sequencing Instrumentation
3.3.1 Instrumentation Tenacity
3.3.2 Declining Cost of Instruments Changes Industry Structure
3.3.3 Listing of Current Instrument Specifications
3.3.4 Long Reads - Further Segmentation
3.3.5 Linked Reads
3.3.6 New Sequencing Technologies
4. Human Gene Sequencing Recent Developments
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
Genetron Health Targeting Early Cancer Detection
Pan-European Initiative to Build Tools for Sharing Genomic Data
UK Government Unveils New Genomic Healthcare Strategy
Foundation Medicine Liquid Biopsy Gets FDA Approval
American Heart Association Develops Genetic Testing Guidelines
Yourgene Health Gets CE Mark for Iona NIPT Test
NorthShore Looks to Expand Genomics Integration Into Primary Care
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients
FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
BillionToOne Closes $15M Series A Follow-on Round
Mass General, Brigham and Women's Open Clinics to Integrate Genomics Into Primary Care
Asuragen Fragile X Diagnostic Test Gets FDA Authorization
Fluxion Bio Wins NIH Grant to Develop NIPT Assay
Illumina, Broad Institute Collaborate on Genome Analysis Software
Illumina, Adaptive Biotechnologies Partner on IVD Test Kits for Immune Sequencing
Menarini Silicon Biosystems, BlueBee Partner on Sequencing Data Analysis Platform
Paying cash for elective genomic sequencing
NIH funds Color ahead of million-person sequencing effort
Veritas Genetics slashes price of whole genome sequencing 40% to $600
Superfast gene sequencing diagnoses critically ill patients
Veracyte Details Clinical Utility of RNA Sequencing-Based Testing for Thyroid Cancer
Longas Technologies Launches. Offers 'Virtual Long Read' Library Prep
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive Health Management
Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests
PGDx and PathGroup Enter Co-Development Agreement
Newborn genomic sequencing detects unanticipated disease risk factors
5. Profiles of Key Companies
Genomics, Inc
23andME Inc
Abbott Diagnostics
AccuraGen Inc
Adaptive Biotechnologies
Admera Health, LLC
Agena Bioscience, Inc
Agilent
Akonni Biosystems
Ancestry.com LLC
Anchor Dx
ArcherDx, Inc
ARUP Laboratories
Asuragen
Baylor Miraca Genetics Laboratories
Beckman Coulter, Inc.
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bioarray Genetics
Biocept, Inc
Biodesix Inc
BioFluidica
BioGenex
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bio-Rad Laboratories, Inc.
Bio-Techne
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Centogene
Cepheid (now Danaher
Chronix Biomedical
Circulogene
Clinical Genomics
Color Genomics
Complete Genomics, Inc. - A BGI Company
Cynvenio
Dante Labs
Datar Cancer Genetics Limited
Diasorin S.p.A
Epic Sciences
Epigenomics AG
Eurofins Scientific
Excellerate Bioscience
Exosome Diagnostics
Fabric Genomics
Fluidigm Corp
Foundation Medicine
Freenome
FUJIFILM Wako Diagnostics
Fujirebio
GE Global Research
GE Healthcare Life Sciences
Gene by Gene, Ltd
Genedrive
GeneFirst Ltd.
Genetron Health (Beijing) Co., Ltd.
Genewiz
Genomic Health
Genomics England
Genomics Personalized Health (GPH)
GenomOncology
Genzyme Corporation
Grail, Inc
Grifols
Guardant Health
Guardiome
HeiScreen
Helix
Helomics
Hologic
Horizon Discovery
HTG Molecular Diagnostics
Human Longevity, Inc. iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invitae Corporation
Invivoscribe
Karius
Macrogen
MDNA Life SCIENCES, Inc
MDx Health
Medgenome
Meridian Bioscience
Mesa Biotech
MIODx
miR Scientific
MNG Labs
Molecular MD
NantHealth, Inc
Natera
Nebula Genomics
NeoGenomics
New Oncology
Novogene Bioinformatics Technology Co., Ltd
Omega Bioservices
OncoDNA
ORIG3N, Inc
Origene Technologies
Oxford Nanopore Technologies
Pacific Biosciences
Panagene
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
PrecisionMed
Promega
Protagen Diagnostics
Qiagen Gmbh
Quantumdx
Regeneron
Roche Molecular Diagnostics
Roswell Biotechnologies
Seegene
Sequencing.com
Siemens Healthineers
simfo GmbH
Singlera Genomics Inc
SkylineDx
Stratos Genomics
Sure Genomics, Inc
Sysmex
Sysmex Inostics
Tempus Labs, Inc
Thermo Fisher Scientific Inc
Veritas Genetics
Volition
6. The Global Market for Human Genome Sequencing
6.1 Global Market Overview by Country
6.2 Global Market by Application - Overview
7. Market Sizes by Application
7.1 Hereditary Gene Sequencing Market
7.2 Newborn Gene Sequencing Market
7.3 NIPT Gene Sequencing Market
7.4 Oncology Gene Sequencing Market
7.5 Pharmacogenomic Gene Sequencing Market
7.6 Direct To Consumer Gene Sequencing Market
8. Vision of the Future of Human Gene Sequencing
For more information about this report visit https://www.researchandmarkets.com/r/rpfs5z
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900